Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557967 · ClinicalTrials.gov registry record
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
A clinical trial of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 22,517
- Enrollment target
- 1
- Study location
NCT06557967: Completed study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.
NCT06557967 is a study of Non-Small Cell Lung Cancer and Lung Cancer that has completed, run by Daiichi Sankyo. The registered enrollment target is 22,517 participants, above the 603-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (3634% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06557967, a study of Non-Small Cell Lung Cancer and Lung Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 22,517 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Conditions Studied
Interventions
- OTHER No drug
Study Locations (1)
Massachusetts
- ConcertAI Database - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,517 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2024-09-30 |
What the finished NCT06557967 record still lists
NCT06557967 is an observational study that tracks outcomes without assigning an intervention. Its 22,517 participants enrollment target places it among the larger protocols in the corpus, above the 603-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (3634% higher).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which No drug is the first listed.
NCT06557967 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06557967 about?
NCT06557967 is a clinical study titled "Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment". This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
What is the current status of trial NCT06557967?
This trial is currently completed. The enrollment target is 22,517 participants. The study started on 2024-03-01. Estimated completion is 2024-09-30.
What conditions does trial NCT06557967 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer.
What interventions are being tested in trial NCT06557967?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06557967?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557967 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06557967's enrollment target sits among peer trials
22,517 2nd of 454 the highest of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI